Rapid Response Lactate Sensor for Heart Recovery Patients
NineSigma, representing Abiomed, the global leader in heart pump technology, invites proposals from organizations and researchers for a real-time lactate bio-sensor which can be inserted in the arterial blood flow.
Fluctuation in blood lactate levels is a key biomarker when monitoring a heart recovery patient. Primary Care Providers would like to monitor the lactate in real-time but issues with current available devices relating to stability, response time and/ or bio-compatibility have prevented the clinical viability of these devices.
Being able to monitor lactate in real time will allow physicians to detect clinical deterioration much earlier, thus allowing for a more timely response, better-informed medical treatment decisions, and improved patient outcomes.
Abiomed are looking for advanced, real-time lactate sensors which are stable in the arterial blood flow for minimum of 12 hours. The ideal device would be licensed by Abiomed, but development of potential technologies would also be welcomed.
Whilst development projects are welcomed, proposers would be expected to have knowledge of ISO 10993 and medical device verification
Key Success Criteria
Continuous lactate monitoring for >12 hours (ideally up to 4 days)
Linear range 1-6 mM
Error <0.4 mM
Response time < 10 minutes (ideal solution would require <1min or zero lag)
Maximum Diameter = 1mm
Deployment time of sensor < 30mins
Biocompatible with insertion in arterial blood flow
Minimal calibration (<1/day); zero calibration ideal
Minimum shelf life of 6 months from point of manufacture
The potential solution providers could be from one of the following sectors (but not limited to)
Lactate sensors for sports medicine
Medicine / Health sensors
Academic animal studies
Contract Medical manufacturers
Approaches not of Interest
Items to be Submitted
All proposals should be submitted online via Ninesights, the NineSigma open innovation community, according to the instructions in the Proposal Template. Proposals should contain the following
Detailed description of technology and potential application for heart patients
Compare and contrast with the detailed specifications listed
Evidence of clinical or preclinical data
Development plans to reach target
Status of IP and Freedom to operate
Brief overview of organization
Experience of commercial exploitation medical devices